Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations.

ABSTRACT:

Background

Somatic genetic alterations of the estrogen receptor 1 gene (ESR1) are enriched in endocrine therapy-resistant, estrogen receptor-positive (ER+) metastatic breast cancer (mBC). Herein, we investigated and compared the clinical and genomic landscape of ESR1-mutant (ESR1^MUT) and ESR1 wild type (ESR1^WT) ER+/ human epidermal growth factor receptor 2 (HER2)- mBCs.

Methods

Clinical and genomic data were retrieved from cBioPortal using the publicly-available MSK MetTropism dataset. Metastatic, ER+/HER2- mBC samples were included in the analysis. Only oncogenic and likely oncogenic alterations according to OncoKB were included. Statistical analyses were carried out using alpha level of 0.05, with a false discovery rate threshold of 10% for multiple c

SUBMITTER: Boscolo Bielo L 

PROVIDER: S-EPMC11480226 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature